Massive revenue growth, surging margins, and groundbreaking cancer breakthroughs--Natera's unstoppable rise is turning heads ...

Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

And we were excited to see presentation of data at the World Conference of Lung Cancer and ESMO showing promising efficacy ...

They also highlighted the recently initiated Phase 1/2 trial of GEN-1057 in malignant solid tumors. At the ESMO conference, ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

New results from a pooled analysis of patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials will be featured in a late-breaking presentation at the ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

Researchers demonstrate AI-enhanced MRI's potential in diagnosing endometrial cancer, achieving superior accuracy and ...

Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ETCompany ParticipantsBill Anderson - Chairman & CEOWolfgang Nickl ...

In July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its BLA for cosibelimab as a complete response to the complete response letter (“CRL”) issued in December 2023 ...